CPH Set to Expand cannaQIX® Product Line After Major Technological Breakthrough
Feb 06, 2020
Hot on the heels of major developments in human and animal health, Creso Pharma (ASX:CPH) has achieved another key milestone: a technological breakthrough that will expand its cannaQIX® human health product line,
CPH’s cannaQIX® Products Have Now Exceeded the 2.5 million Lozenges Sold Milestone
Jan 28, 2020
Creso Pharma (ASX:CPH, FRA:1X8) has announced its second major milestone for the year. Today is has informed the market that its flagship cannaQIX® line surpassed the milestone of 100,000 packs sold. The 100,000 pack milestone corresponds to over 2.5 million cannaQIX® lozenges sold since the product’s launch in April 2018.
IMU Poised to Break into Oncolytic Virotherapy Space with Novel Cancer Therapy
Oct 24, 2019
The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.
GTG Signs Prestigious Collaboration Agreement for Fight Against Cancer
Oct 02, 2019
Emerging med-tech junior Genetic Technologies (ASX:GTG | NASDAQ:GENE) understands the importance of timely and precise targeting. Accessible predictive risk testing is where GTG lives and it has now signed a 3-year Collaboration Agreement with high profile US-based researcher Translational Genomics Research Institute (TGen).
Could a Loxo Oncology Style Trial, Bring Loxo Style Results for PTX?
Jan 31, 2019
Clinical stage oncology company, Prescient Therapeutics (ASX:PTX) is in a fortunate position. It has two clinical candidates, four trials, and multiple possible pathways to market for its targeted therapies that address specific mutations that drive cancer and contribute to resistance.
Imugene Meets All Endpoints in Phase 1b Gastric Cancer Immuno-oncology Trial: Tumour Reduction In Gastric Cancer
Dec 17, 2018
Imugene (ASX:IMU) has now released results from the Phase 1b Gastric Cancer trial, showing that all dose levels of its HER-Vaxx cancer vaccine showed an increase in antibodies in patients.